Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## Why UnitedHealthcare Denied an Immune Checkpoint Inhibitor as Duplicate Therapy — and How to Appeal

Immune checkpoint inhibitors — including pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), atezolizumab (Tecentriq), durvalumab (Imfinzi), and cemiplimab (Libtayo) — each target distinct immune checkpoints (PD-1, PD-L1, or CTLA-4) and have different FDA-approved indications and combination regimens. UnitedHealthcare (UHC) may issue a duplicate-therapy denial when it determines that another checkpoint inhibitor or an overlapping immunotherapy is already covered, authorized, or dispensed. This denial is often based on an automated formulary or utilization-management system flag rather than a clinical review of your specific regimen.

## Why This Denial Is Appealable

Duplicate-therapy denials for checkpoint inhibitors are frequently overturned because the agents in this class are not interchangeable: they have different targets, different FDA-approved indications, different companion diagnostic requirements, and different safety profiles. A combination regimen (e.g., a PD-1 inhibitor plus a CTLA-4 inhibitor) is not "duplicate therapy" — it is an evidence-based multi-agent regimen with a distinct FDA approval. Your prescribing oncologist must document the clinical distinction. Under ERISA §503, self-funded employer plans must provide a full and fair review. Under ACA §2719, non-grandfathered insured plans must allow independent external review.

## Federal Appeal Framework

• Internal appeal deadline: Check your Explanation of Benefits (EOB) for the exact deadline — typically 180 days from denial for non-urgent matters.
• Urgent/expedited: If treatment delay would seriously jeopardize your health, request expedited internal review (decision within 72 hours) and simultaneous external review.
• External review: After exhausting (or being deemed to have exhausted) internal appeals, request independent external review under ACA §2719. A neutral oncology-credentialed reviewer will evaluate whether the denial was clinically appropriate.
• State insurance department: File a parallel complaint with your state insurance commissioner.

## Documentation to Gather

• Oncologist letter distinguishing the agents: Your oncologist must explain why the requested agent is not duplicative — specifically, the target (PD-1 vs. PD-L1 vs. CTLA-4), the FDA-approved indication for your tumor type and biomarker status, and why the regimen is consistent with the applicable NCCN guideline category recommendation.
• Pathology and biomarker results: Tumor type, stage, histology, and any companion diagnostic results (e.g., PD-L1 expression, MSI/dMMR status, TMB) that support the specific agent or combination selected.
• Current treatment plan: Documentation of all agents currently authorized or dispensed, and the clinical rationale for adding or substituting the requested agent.
• FDA prescribing information: Attach the indication section from the requested agent's FDA label showing it is approved for your specific tumor type and clinical setting.
• NCCN guideline category: Your oncologist should reference the applicable NCCN recommendation category for your tumor type and regimen without quoting specific statistics.

## Criteria-Mapping Structure

Request UHC's clinical coverage determination policy for the specific agent and build a point-by-point response:

| UHC Denial Basis | Your Documentation | |---|---| | Alleged duplication with agent X | Oncologist letter: distinct mechanism/target | | Same therapeutic class | FDA label showing distinct indication | | Combination not covered | NCCN category + FDA combination approval | | Biomarker requirement | Pathology/companion diagnostic result |